Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Re: Exelon acquisition
View:
Post by curiousj on Jun 10, 2021 12:05pm

Re: Exelon acquisition

considering the price paid for Exelon, do you think given the news from Biogen, that Knight paying 3.8x sales for the product was too much? Especially knowing that Novartis can still compete with Knight through Sandoz
Comment by MrMugsy on Jun 10, 2021 12:14pm
And ... Demand may grow up to 10x by 2050 And ... The potential to enter smaller geographies is certainly a GUD focus And ... GUD promotion will have a positive effect on sales growth Oh ... and ... future partnerships with Novartis are likely - new Exelon sales in ROW geographies may seal a bigger deal for other Novartis drugs.
Comment by MrMugsy on Jun 10, 2021 12:23pm
Sorry Curious ... I just realized that you were asking a question ... while I was adding points to why there's likely success in this acquisition.  I think there is lots of room to compete with Sandoz and there are countries where we can likely take the lead.  Probably comes down to the ability of the sales/marketing teams. Also, are there any other motives for buying the IP and ...more  
Comment by Chianchin on Jun 11, 2021 7:54am
Biogen (BIIB) – Biogen added 1.4% in the premarket after UBS upgraded the drug maker’s stock to “buy” from “neutral,” and Bernstein raised its rating to “outperform” from “market perform.” Both firms base their upgrades on the potential sales bump from the Food and Drug Administration’s approval this week of Alzheimer’s disease treatment Aduhelm.
Comment by Spirou25 on Jun 11, 2021 8:14am
You are pathetic. Two options : 1) You're paid to post here. 2) You need to take medication.
Comment by Chianchin on Jun 11, 2021 1:20pm
Patetic? Simply reprting the Bermstein Firm upgrade of Biogem. It is a simple a zero sum game/business  situation where losses of business incurred by a company/player in transactions/sales  result in an equal increase in gains/sales of the opposing company player. Simple math
Comment by schocor on Jun 11, 2021 1:26pm
Are you expecting latin America to approved Biogem? Seriously? What is your timeline for this approval look like? I am expecting "crickets".
Comment by Spirou25 on Jun 11, 2021 2:02pm
The two drugs don't even compete
Comment by Chianchin on Jun 11, 2021 3:01pm
Most midle class Latam resident travel to South Florida. The first spoken laguage there is espagnol and half of the condos are owned by person living in Latam. They also got vaccinated way before we did in Canada. They care about their seniors a lot in Latam. Try to read Latam news and save yourself some more $$ losses
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities